Spots Global Cancer Trial Database for napabucasin
Every month we try and update this database with for napabucasin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | NCT03522649 | Previously Trea... | Napabucasin Fluorouracil Leucovorin Irinotecan | 18 Years - | 1Globe Biomedical Co., Ltd. | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| Special Combination of BBI608 and Pembrolizumab | NCT02851004 | Metastatic Colo... | Napabucasin Pembrolizumab | 20 Years - | National Cancer Center Hospital East | |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 | Carcinoma, Non-... | Napabucasin Paclitaxel | 18 Years - | Sumitomo Pharma America, Inc. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | NCT04299880 | Oncology | Napabucasin Nab-paclitaxel Gemcitabine Nivolumab Paclitaxel Irinotecan Leucovorin 5Fluorouracil Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. | |
| Special Combination of BBI608 and Pembrolizumab | NCT02851004 | Metastatic Colo... | Napabucasin Pembrolizumab | 20 Years - | National Cancer Center Hospital East | |
| Special Combination of BBI608 and Pembrolizumab | NCT02851004 | Metastatic Colo... | Napabucasin Pembrolizumab | 20 Years - | National Cancer Center Hospital East | |
| Special Combination of BBI608 and Pembrolizumab | NCT02851004 | Metastatic Colo... | Napabucasin Pembrolizumab | 20 Years - | National Cancer Center Hospital East | |
| A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | NCT03522649 | Previously Trea... | Napabucasin Fluorouracil Leucovorin Irinotecan | 18 Years - | 1Globe Biomedical Co., Ltd. | |
| A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | NCT02753127 | Colorectal Canc... | Napabucasin Fluorouracil Leucovorin Irinotecan Bevacizumab | 18 Years - | Sumitomo Pharma America, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
